Related by context. All words. (Click for frequent words.) 72 atypical Hemolytic Uremic Syndrome 67 lupus nephritis 67 atypical hemolytic uremic syndrome 66 paroxysmal nocturnal hemoglobinuria PNH 66 NYHA Class II 65 AA amyloidosis 64 indolent NHL 64 metastatic malignant melanoma 64 neurological manifestations 64 myelodysplastic syndrome MDS 64 leukemia AML 64 Myelofibrosis 64 acute myelogenous leukemia AML 63 Ribavirin causes 63 Atypical Hemolytic Uremic Syndrome 63 invasive fungal infections 63 Diabetic Macular Edema 63 chronic ITP 63 hematologic disorders 63 gastrointestinal stromal tumor GIST 63 Fabry Disease 63 EXJADE 63 sJIA 63 purpura ITP 63 Dacogen injection 63 MPS VI 63 immunomodulatory therapy 63 erlotinib Tarceva ® 63 leukemia CLL 63 recurrent glioblastoma 63 homozygous familial hypercholesterolemia 63 Primary IGFD 62 hypercalcemia 62 severe malignant osteopetrosis 62 OHR/AVR# 62 metastatic renal cell carcinoma 62 cell lymphoma CTCL 62 HeFH 62 Bronchiectasis 62 pancytopenia 62 acute GvHD 62 pheochromocytoma 62 NAGS deficiency 62 systemic lupus erythematosus 62 Severe Primary IGFD 62 myelodysplastic syndromes MDS 62 relapsed refractory multiple myeloma 62 chronic HCV infection 62 homozygous FH 62 chronic plaque psoriasis 62 myelofibrosis 62 failure ADHF 62 AA Amyloidosis 62 eosinophilic asthma 62 esophageal candidiasis 62 familial amyloidotic polyneuropathy FAP 61 idiopathic thrombocytopenic purpura ITP 61 pancreatic insufficiency 61 immune thrombocytopenic purpura ITP 61 systemic juvenile idiopathic 61 recurrent glioblastoma multiforme 61 myeloproliferative diseases 61 chronic lymphocytic leukemia CLL 61 amrubicin 61 chronic GVHD 61 invasive candidiasis 61 cutaneous T 61 relapsing remitting multiple sclerosis 61 Enzyme Replacement Therapy 61 idiopathic pulmonary fibrosis IPF 61 pancreatic NET 61 systemic lupus erythematosus SLE 61 ischemic cardiomyopathy 61 carcinoid syndrome 61 vWD 61 metastatic malignant 61 recurrent malignant glioma 61 standard chemotherapy regimens 61 eculizumab 61 chemotherapy induced neutropenia 61 myeloproliferative disorders 61 DMARDS 61 refractory gout 61 MELAS 61 GvHD 61 hemorrhagic cystitis 61 HoFH 61 mRCC 61 Acute Myelogenous Leukemia AML 61 candidemia 61 Lupus nephritis 61 non alcoholic steatohepatitis 61 GISTs 61 imatinib resistant 61 infantile spasms 61 terlipressin 61 TORISEL 61 PEGINTRON TM 61 cilengitide 61 phase IIb clinical 61 bendamustine 61 acute decompensated heart 61 acute myeloid leukemia AML 61 PAOD 61 riociguat 61 severe gastroparesis 61 refractory NSCLC 61 T#I mutation 61 Juvenile Idiopathic Arthritis JIA 61 receptor tyrosine kinase inhibitor 61 dirucotide MBP# 61 hypereosinophilic syndrome 61 leukemia CML 61 immunocompromised patients 61 chronic eosinophilic leukemia 60 docetaxel chemotherapy 60 superficial bladder cancer 60 posterior uveitis 60 potentially hepatotoxic 60 TELINTRA 60 relapsed AML 60 cIAI 60 Navelbine ® 60 tumor lysis syndrome 60 subependymal giant cell 60 VEGF inhibitors 60 T2DM 60 INCB# [003] 60 chronic granulomatous disease 60 Toxicities 60 ADPKD 60 Plicera 60 TNF antagonist 60 thyrotoxicosis 60 dirucotide 60 invasive aspergillosis 60 anterior uveitis 60 ribavirin therapy 60 symptomatic BPH 60 non metastatic osteosarcoma 60 lymphoma CTCL 60 LHON 60 B CLL 60 immune thrombocytopenic purpura 60 myelodysplastic syndromes 60 hypoparathyroidism 60 hypophosphatasia 60 exocrine pancreatic insufficiency 60 relapsed multiple myeloma 60 inhibitor RG# 60 haematological malignancies 60 mixed dyslipidemia 60 Chronic lymphocytic leukemia 60 rheumatoid arthritis psoriatic arthritis 60 hematopoietic cell 60 Acute Myeloid Leukemia AML 60 chronic immune thrombocytopenic 60 juvenile idiopathic arthritis 60 hereditary antithrombin deficiency 60 dopaminergic therapy 60 pomalidomide 60 Leber Hereditary Optic Neuropathy 60 decompensated heart failure 60 rALLy 60 refractory chronic lymphocytic 60 chronic renal failure 60 gastrointestinal stromal tumors GIST 60 complement inhibitor eculizumab 60 chronic ITP patients 60 Gleevec resistant 60 CLL SLL 60 metastatic GIST 60 nilotinib 60 heterozygous FH 60 Myelodysplastic Syndrome MDS 60 cetuximab Erbitux ® 60 juvenile idiopathic arthritis JIA 60 MPS IVA 60 myelofibrosis polycythemia vera 60 nephropathic cystinosis 60 mildly symptomatic 60 immune idiopathic thrombocytopenic 59 angiographic outcomes 59 lintuzumab SGN 59 visilizumab 59 dasatinib Sprycel ® 59 Cushing syndrome 59 MALT lymphoma 59 haematologic 59 benign prostatic hypertrophy BPH 59 intracranial hemorrhage ICH 59 drug ISA# 59 essential thrombocythemia 59 basiliximab 59 Major Depressive Disorder MDD 59 brivaracetam 59 RoACTEMRA 59 pathologic myopia 59 grade cervical intraepithelial 59 rFVIIa 59 unresectable 59 allogeneic bone marrow 59 lactic acidosis 59 paroxysmal nocturnal hemoglobinuria 59 Hematologic 59 cytopenias 59 REMICADE ® 59 relapsed leukemia 59 IV NSCLC 59 pancreatic neuroendocrine tumors 59 Hodgkin lymphoma NHL 59 Phenoptin 59 Fibrillex TM 59 neuroendocrine tumors 59 osteosarcoma Ewing sarcoma 59 neurogenic bladder 59 lomitapide 59 Thrombocytopenia 59 neutropenia dehydration dyspnea 59 SJIA 59 Actemra tocilizumab 59 stage IIIB 59 hyperkalemia 59 Amrubicin 59 relapsed MM 59 Doxil ® 59 gastrointestinal mucositis 59 retinal vein occlusion 59 tyrosine kinase inhibitors TKIs 59 refractory CLL 59 painful diabetic neuropathy 59 necrotizing pancreatitis 59 efalizumab 59 elotuzumab 59 lysosomal storage diseases 59 nosocomial pneumonia 59 either acutely decompensated 59 ponatinib 59 Torisel 59 Behcet uveitis 59 MYDICAR ® 59 Cloretazine 59 phase IIb trial 59 Cutaneous T 59 transplantation HCT 59 PSVT 59 papillary renal cell carcinoma 59 rilonacept 59 metastatic neuroendocrine tumors 59 SPRYCEL ® 59 antibody mediated rejection 59 Annamycin 59 nonsense mutation 59 valvular disease 59 glomerulonephritis 59 C1 INH 59 proliferative diabetic retinopathy 59 cutaneous T cell 59 CRVO 59 calcineurin inhibitors 59 metastatic hormone refractory 59 Clofarabine 59 myeloproliferative neoplasms 59 grade glioma 59 deletion 5q 59 unstable angina UA 59 chronic myeloid leukemia CML 59 secondary hyperparathyroidism 59 neurogenic orthostatic hypotension 59 HBeAg negative 59 Certolizumab pegol 59 adrenal insufficiency 59 docetaxel Taxotere ® 59 Epratuzumab 59 autoantibody positive 59 Traficet EN 59 hepatocellular carcinomas 59 GEM OS2 59 catheter occlusion 59 reslizumab 59 hyperphenylalaninemia HPA due 59 Neovascular AMD 59 immunodeficiency 59 GEM OS1 59 severe hypersensitivity reactions 59 cell lymphoma ALCL 59 hepatocellular carcinoma HCC 59 Eculizumab 59 metastatic HRPC 59 ALT flares 59 hoFH 59 Hemophilia B 58 elacytarabine 58 hemolytic anemia 58 hematologic toxicity 58 Myelodysplastic Syndrome 58 symptomatic benign prostatic 58 Rheumatoid Arthritis RA 58 allogeneic stem cell 58 diseases chronic granulomatous 58 colorectal liver metastases 58 decompensated liver disease 58 pancreatic adenocarcinoma 58 Host Disease GvHD 58 Soliris eculizumab 58 essential thrombocythemia ET 58 heavily pretreated 58 ANCA associated 58 cystic fibrosis chronic pancreatitis 58 lymphocytosis 58 Sutent sunitinib 58 Cimzia ® certolizumab pegol 58 pediatric Crohn disease 58 stable angina 58 Soft Tissue Sarcoma 58 BENLYSTA ® 58 hypersensitivity reaction 58 recurrent glioma 58 HSCT 58 IL# PE#QQR 58 SinuNase TM 58 imatinib Gleevec ® 58 pulmonary arterial hypertension PAH 58 RSD# oral 58 Nexavar sorafenib 58 transplantation HSCT 58 Phase Ib study 58 relapsed refractory 58 mCRC patients 58 MKC# MT 58 metastatic RCC 58 Eisenmenger syndrome 58 myeloproliferative 58 Friedreich Ataxia FRDA 58 juvenile myoclonic epilepsy 58 chronic myocardial ischemia 58 severe hypercholesterolemia 58 nephrotic syndrome 58 Deferiprone 58 prostate cancer CRPC 58 leukemia APL 58 anti angiogenic agents 58 SUPPRELIN R LA 58 leukemia ALL 58 follicular lymphoma FL 58 acute ischemic stroke 58 carcinoid tumors 58 thalidomide Thalomid 58 dasatinib Sprycel 58 gastrointestinal stromal tumor 58 carcinoid 58 Evoltra TM 58 naïve HCV 58 IBS C 58 myotonic muscular dystrophy 58 gastrointestinal stromal tumors 58 AEG# 58 TTR amyloidosis 58 MPGN 58 tuberous sclerosis TS 58 therapeutic regimens 58 Acute Radiation Syndrome ARS 58 calcineurin inhibitor 58 purpura 58 Peginterferon alfa 2b 58 thyroiditis 58 Fludara ® 58 non splenectomized 58 CMV disease 58 CYT# potent vascular disrupting 58 soft tissue sarcomas 58 smoldering multiple myeloma 58 docetaxel Taxotere R 58 proliferative retinopathy 58 azacitidine 58 Uricase PEG 58 CIMZIA ™ 58 eculizumab therapy 58 Cell Lymphoma 58 recurrent NSCLC 58 FOLFOX chemotherapy 58 acute coronary syndromes ACS 58 aortic valve stenosis 58 hereditary deficiency 58 imatinib therapy 58 acute humoral rejection 58 keloid scarring 58 HCV genotype 58 follicular lymphomas 58 Paroxysmal Nocturnal Hemoglobinuria PNH 58 Kepivance 58 imatinib Gleevec 58 beta thalassemia 58 ADHF 58 atherothrombotic events 58 HBeAg positive 58 unfavorable cytogenetics 58 cSSSIs 58 noninfectious uveitis 58 kidney urologic 58 bone marrow suppression 58 occlusion CRVO 58 Aviptadil 58 alvespimycin 58 grade cervical dysplasia 58 hyperoxaluria 58 grade gliomas 58 EGFR inhibitors 58 Fludarabine 58 Chronic Myeloid Leukemia 58 alpha interferons 58 Velcade bortezomib 58 deferiprone 58 TKI therapy 58 somatostatin analogue 58 CTEPH 58 relapsed ovarian cancer 58 primary hypercholesterolemia 58 oxypurinol 58 metaglidasen 58 Dasatinib 58 Dacogen decitabine 58 Carcinoid tumors 58 prokinetic agent 58 Hurler syndrome 58 VAPRISOL 58 refractory metastatic colorectal cancer 58 Omacetaxine 58 diabetic macular edema DME 58 Clolar ® 58 neuroendocrine cancers 58 immunosuppressed patients 58 tumor xenograft models 58 Glioblastoma Multiforme 58 lymphocytic leukemia 58 refractory anaplastic astrocytoma 58 PTLD 58 relapsing remitting 58 relapsed acute myelogenous 58 ribavirin RBV 58 unknown etiology 58 chronic HCV 58 severe Primary IGFD 58 neovascular 57 chronic HBV infection 57 acute aortic dissection 57 delayed CINV 57 TBC# 57 Acute Bacterial Sinusitis ABS 57 myelodysplastic myeloproliferative diseases 57 recurrent GBM 57 BCG refractory 57 immunocompetent patients 57 baminercept 57 allograft rejection 57 Zavesca 57 panitumumab Vectibix 57 bevacizumab Avastin ® 57 lupus erythematosus 57 mCRC 57 post herpetic neuralgia PHN 57 tyrosine kinase inhibitor TKI 57 uveitis 57 familial hypercholesterolemia 57 corticosteroid therapy 57 dilated cardiomyopathy DCM 57 thromboembolic complications 57 herpes zoster shingles 57 paraganglioma 57 acromegaly 57 Acute Decompensated Heart Failure 57 Sezary syndrome 57 axitinib 57 refractory epilepsy 57 hepatic encephalopathy 57 overactive bladder syndrome 57 systemic anaplastic large 57 Philadelphia Chromosome Positive 57 metastatic lung cancer 57 primary immunodeficiency PI 57 YONDELIS 57 ATIR 57 severe sepsis 57 myeloid 57 teriflunomide 57 dyskeratosis congenita 57 sodium thiosulfate STS 57 hepatic metastases 57 angioedema 57 subcutaneous formulation 57 adverse cytogenetics 57 Etanercept 57 Chronic Myeloid Leukemia CML 57 PNH patients 57 allogeneic hematopoietic stem cell 57 vitreous hemorrhage 57 lumiliximab 57 hyperuricemia 57 phenylketonuria PKU 57 hypercalcaemia 57 severe neutropenia 57 basal cell nevus syndrome 57 TYZEKA 57 preserved ejection fraction 57 mycophenolate mofetil 57 hypomethylating agents 57 castrate resistant prostate cancer 57 Lennox Gastaut syndrome 57 hormone refractory prostate cancer 57 chorea associated 57 pan HDAC inhibitor 57 HGS# 57 octreotide implant 57 denileukin diftitox 57 Xanafide 57 hematological malignancy 57 cytopenia 57 metastatic uveal melanoma 57 phase IIa clinical 57 hepatorenal syndrome 57 Alzhemed TM 57 Ceflatonin R 57 PEG PAL 57 retinal dystrophies 57 diabetic nephropathy 57 Onrigin 57 Pulmonary Arterial Hypertension PAH 57 fallopian tube carcinoma 57 histone deacetylase HDAC inhibitor 57 Natalizumab 57 epilepsies 57 mTOR inhibitor 57 refractory cutaneous T 57 relapsing multiple sclerosis 57 tafamidis 57 null responder HCV 57 refractory AML 57 PEGylated interferon beta 1a 57 lysosomal storage disease 57 Troxatyl 57 Gel repository corticotropin injection 57 Revimmune 57 thrombolytic agents 57 onset diabetes mellitus 57 tocilizumab 57 unresectable tumors 57 Gleevec imatinib mesylate 57 relapsed ALL 57 Entereg R 57 schizophrenia CIAS 57 JAK1 57 sunitinib malate 57 skeletal metastases 57 gastric carcinoma 57 Staphylococcus aureus infections 57 NOMID 57 smoldering myeloma 57 infective endocarditis 57 late onset Pompe 57 Systemic Lupus Erythematosus SLE 57 pulmonary hypertension PH 57 Noxafil 57 octreotide 57 pulmonary arterial hypertension 57 Chronic Heart Failure 57 induced macular edema 57 gastrointestinal perforation 57 psoriatic arthritis PsA 57 geographic atrophy 57 CEQ# 57 nucleoside analogues 57 dasatinib 57 leukoencephalopathy 57 nephropathy 57 relapsing remitting MS RRMS 57 juvenile myelomonocytic leukemia 57 taxane resistant 57 pemphigus vulgaris 57 pegylated interferons 57 investigational monoclonal antibody 57 Proxinium TM 57 relapsed SCLC 57 receiving immunosuppressive therapy 57 huC# DM4 57 osteosarcomas 57 short bowel syndrome 57 hepatocellular cancer 57 myeloproliferative disorder 57 proteasome inhibitor 57 diabetic gastroparesis 57 idiopathic thrombocytopenic purpura 57 T#I [002] 57 severe mitral regurgitation 57 tumors GIST 57 vertebral compression fractures 57 Maroteaux Lamy syndrome 57 Syndrome LEMS 57 metastatic castration resistant 57 Hereditary angioedema HAE 57 hyperprolactinemia 57 Zenvia TM 57 TRISENOX ® 57 IV metastatic melanoma 57 onset seizures 57 debilitating complication 57 Augment Injectable 57 ruboxistaurin 57 LHRH analogues 57 Wegener granulomatosis 57 posaconazole 57 anemia neutropenia 57 MULTAQ 57 CTAP# Capsules 57 gouty arthritis 57 pericardial effusion 57 OMNARIS HFA 57 AAT deficiency 57 romiplostim 57 virus HCV infection 57 fibrotic disease 57 platinum refractory 57 depression TRD 57 Torsades de Pointes 57 forodesine 57 hematologic malignancies 57 stable angina pectoris 57 acute leukemias 57 diffuse intrinsic pontine glioma 57 refractory angina 57 Myelodysplastic syndromes 57 cangrelor 57 HCV RESPOND 2 57 macroalbuminuria 57 leukaemias 57 exocrine pancreatic insufficiency EPI 57 cetuximab Erbitux R 57 PLX cells 57 hypercholesterolaemia 57 PD LID 57 Lambert Eaton Myasthenic 57 TMS Therapy 57 BARACLUDE ® 57 diabetic neuropathic pain 57 gemcitabine Gemzar 57 Icatibant 57 vidofludimus 57 Chronic Myelogenous Leukemia CML 57 urocortin 2 57 chronic HBV 57 chlorambucil 57 partial onset seizures 57 PDX pralatrexate 57 anthracycline containing 57 pharmacokinetic interactions 57 bardoxolone 57 underwent resection 57 GW# [003] 57 pegfilgrastim 57 systemic lupus erythematosus psoriasis 57 Soliris TM eculizumab 57 IMA# 57 antithrombotics 57 IGFD 57 epithelial tumors 57 graft dysfunction 57 rheumatoid arthritis Crohn disease 57 hematological diseases 57 methylnaltrexone 57 Zavesca R 57 Crohn disease CD 57 Ph + ALL 57 cardiogenic shock 57 proliferative disorders 57 MGd 57 symptomatic paroxysmal AF 57 medullary thyroid cancer 57 Kit CD# positive 57 chronic pancreatitis CP 57 Chronic Lymphocytic Leukemia CLL 57 Aryplase 57 resectable 56 NYHA Class III 56 hyperparathyroidism 56 HCV infection 56 SHPT 56 diarrhea predominant irritable 56 constipation predominant irritable bowel 56 RSV infections 56 squalamine 56 HuLuc# 56 nab paclitaxel 56 phenylketonuria 56 MYCN amplification 56 gemcitabine Gemzar ® 56 cerebral vasospasm 56 JMML 56 curative resection 56 Onalta ™ 56 von Willebrand disease 56 Retinopathy 56 LymphoStat B belimumab 56 immunodeficiency disorders 56 diabetic retinopathy DR 56 malignant ascites 56 uremic pruritus 56 Romiplostim 56 polyposis 56 situ CIS 56 FOLFIRI 56 adult chronic ITP 56 progressive neurodegenerative disorder 56 CA4P 56 prostate cancer HRPC 56 Juvenile Idiopathic Arthritis 56 intravesical therapy 56 ISTODAX 56 systemic fungal infections 56 phase III ACCLAIM 56 squamous cell lung cancer 56 blepharospasm 56 anthracyclines taxanes 56 systemic ALCL 56 refractory chronic myeloid 56 TEMODAL 56 Acute Myeloid Leukemia 56 INVANZ 56 lymphadenopathy 56 PNP inhibitor 56 pericardial effusions 56 Evoltra ® 56 K ras mutations 56 primary generalized tonic 56 SomatoKine 56 acetonide FA 56 refractory APL 56 oropharyngeal candidiasis 56 hypoperfusion 56 Alport syndrome 56 investigational therapies 56 ribavirin Copegus ® 56 Vidaza ® 56 Alocrest 56 Pivotal Trial 56 renal tumors 56 Idiopathic pulmonary fibrosis 56 imatinib mesylate 56 Zenvia ™ 56 REVLIMID lenalidomide 56 retinal vein occlusion RVO 56 hypercholesterolemic patients 56 lung fibrosis 56 risperidone Risperdal 56 ADP receptor antagonist 56 metastatic CRC 56 zanolimumab 56 FOLOTYN ® 56 arthritis PsA 56 nephrotoxicity 56 hyperammonemia 56 refractory Hodgkin lymphoma 56 Fx #A 56 lenalidomide dexamethasone 56 myeloid metaplasia 56 fungoides 56 CCR5 tropic HIV 56 acute myocardial infarction AMI 56 adalimumab Humira 56 fallopian tube cancers 56 MabCampath 56 mycophenolate mofetil MMF 56 Tolvaptan 56 HCV SPRINT 56 UPLYSO 56 chronic myeloid 56 unstable angina pectoris 56 relapsing remitting MS 56 astrocytomas 56 hepatotoxicity 56 refractory multiple myeloma 56 thymoma 56 ularitide 56 hematological 56 KRAS mutations occur 56 neutropenia thrombocytopenia 56 idarubicin 56 CD# monoclonal antibody 56 delayed onset CINV 56 mapatumumab 56 proctitis 56 budesonide foam 56 Myelodysplastic syndromes MDS 56 oropharyngeal candidiasis OPC 56 GED aPC 56 paroxysmal AF 56 NYHA Class 56 Critical Limb Ischemia CLI 56 irinotecan containing 56 osteopetrosis 56 rituximab Rituxan 56 generation purine nucleoside 56 Ozarelix 56 NATRECOR ® 56 neuropsychiatric symptoms 56 Val HeFT 56 Morquio 56 Lactic acidosis 56 demyelinating disease 56 HuMax CD4 56 NATRECOR R 56 hematological malignancies 56 castration resistant prostate cancer 56 somatostatin analogues 56 Tarceva erlotinib 56 immunosuppressed 56 transthyretin amyloidosis 56 herpetic keratitis 56 Herceptin trastuzumab 56 EGFR HER2 56 dexamethasone Decadron 56 Systemic lupus erythematosus 56 generalized seizures 56 left ventricular dysfunction 56 TTF Therapy 56 LEUKINE 56 hepatocellular carcinoma 56 complete remissions 56 Lixivaptan 56 myelodysplasia 56 unresectable stage 56 Phase #/#a trial 56 EVIZON 56 erythropoietic 56 autosomal recessive disorder 56 TG# [003] 56 generalized edema 56 lymphoproliferative disorder 56 HRPC 56 MKC# MKC# PP 56 bucindolol 56 Insegia 56 endometrial hyperplasia 56 dose cytarabine 56 Psoriatic arthritis 56 lymphoblastic leukemia 56 Raptiva ® 56 thromboembolic events 56 MabThera rituximab 56 postoperative ileus 56 pediatric bipolar disorder 56 hepatitis C genotype 56 Raptiva R 56 Tocilizumab 56 C1 inhibitor deficiency 56 6R BH4 56 tigecycline 56 AAT Deficiency 56 SCCHN 56 acute decompensation 56 pancreatic enzyme replacement 56 hepatitis C HCV 56 Diffuse Large B 56 Nuvion 56 aripiprazole Abilify 56 renal disease 56 lymphoma subtypes 56 TEAEs 56 serologically active systemic lupus 56 ATACAND 56 Acute myeloid leukemia 56 sitaxsentan 56 Cimzia ® 56 steroid refractory GvHD 56 severe renal impairment 56 apricitabine 56 Phase IIIb clinical 56 TELCYTA 56 interferon alfa 2b 56 PEG INTRON R 56 medically inoperable 56 renal insufficiency 56 clofarabine 56 sunitinib 56 paragangliomas 56 interferon therapy 56 Systemic lupus erythematosus SLE 56 Metastatic Colorectal Cancer 56 antiarrhythmic drug 56 Gleevec imatinib 56 HCV infections 56 peginterferon alfa 56 Pivotal Phase III 56 Tasimelteon 56 myelodysplastic syndrome 56 polyneuropathy CIDP 56 polycythemia vera PV 56 Pemetrexed 56 Vascugel 56 investigational compounds 56 atrial arrhythmias 56 chronic renal disease 56 Bezielle 56 Nilotinib 56 dexanabinol 56 hematopoietic malignancies 56 MAGE A3 ASCI 56 biologic therapy 56 NSCLC 56 DMARDs 56 Elagolix 56 Neovascular Age Related Macular 56 mycosis fungoides 56 ocular disorders 56 dose cohorts 56 cSSSI 56 cytogenetic responses 56 bowel resection 56 PI3K/Akt pathway inhibitor 56 telaprevir VX 56 uncontrolled epilepsy 56 Gaucher disease 56 veno occlusive disease 56 Tarceva TM 56 AGILECT R 56 bosentan 56 anemias 56 severe aortic stenosis 56 Rituxan rituximab 56 QTc prolongation 56 dacarbazine 56 de novo kidney transplant 56 metformin accumulation 56 familial adenomatous polyposis 56 systemic amyloidosis 56 diabetes mellitus T2DM 56 multiple myeloma MM 56 ara C 56 aortic dissections 56 choroidal neovascularization 56 2 methoxyestradiol 56 opioid induced constipation OIC 56 low dose cytarabine 56 active ankylosing spondylitis 56 Vidaza R 56 LUX Lung 56 pancreatic carcinoma 56 thalassemia sickle cell 56 serotonergic drugs 56 IPLEX 56 thrombotic thrombocytopenic purpura TTP 56 sarcomas 56 lymphoid malignancies 56 RRMS 56 refractory acute myeloid 56 hepatic failure 55 S. aureus infections 55 tanespimycin 55 malignant neoplasms 55 ELACYT 55 arterial thrombosis 55 heparin induced thrombocytopenia 55 Phase 2b trial 55 haematological cancers 55 Symadex 55 immunocompetent 55 dose regimens 55 Pseudomonas aeruginosa infections 55 cytomegalovirus infection 55 Cimzia TM 55 pulmonary exacerbations 55 Factor VIIa 55 tyrosine kinase inhibitors 55 invasive fungal infection 55 ventricular tachycardia 55 Aflibercept 55 Miraxion 55 transfusion syndrome 55 oral prodrug 55 velaglucerase alfa 55 cognitive impairment associated 55 malignant pleural mesothelioma 55 elevated plasma concentrations 55 Glioblastoma Multiforme GBM 55 renal cell carcinoma 55 GIST tumors 55 certolizumab 55 AGHD 55 tumor necrosis 55 Microplasmin 55 REVLIMID ® 55 pegylated interferon alpha 55 anthracycline taxane 55 targeted radiotherapeutic 55 haematopoietic stem cell 55 erythematosus SLE 55 TASKi3 55 generalized tonic clonic seizures 55 familial hypercholesterolemia FH 55 Letairis ambrisentan 55 CML CP